Researchers and clinicians on campus are transforming the way medications are prescribed for patients. A CU pharmacy expert talks about how and why the scientists are tailoring prescriptions using patient genetics.
In findings recently published in the Journal of Medicinal Chemistry, Daniel LaBarbera, PhD and colleagues describe the optimization of the first lead CHD1L inhibitors (CHD1Li) through drug design and medicinal chemistry.
Omicron cases are rising at staggering rates worldwide, and Colorado, once again, stands out as a national hotspot. But what does this latest SARS-CoV-2 variant carrying a whopping 50 mutations really mean? CU experts try to answer some of those questions as the world of COVID turns.
Krishna Mallela, PhD, and his team received press coverage for the lab’s work on SARS-CoV-2 variants, which focused on the study which highlights the importance of positive and negative selection in evolution of SARS-CoV-2 variants.
Peter Anderson, PharmD spoke with the Guardian about Paxlovid and molnupiravir, which were authorized by the FDA recently. Supplies of Paxlovid are limited while molnupiravir is less effective than hoped, but they are a very important step forward.
Both Pfizer’s Paxlovid and Merck’s molnupiravir are cleared for emergency use in non-hospitalized people who have mild-to-moderate symptoms and are at heightened risk of developing severe disease. Peter Anderson, PharmD spoke with Health regarding their effectiveness.
Manisha N. Patel, PhD, has been installed as First Vice President of the American Epilepsy Society (AES), a medical and scientific professional society with 4,500 members. Dr. Patel’s term started at the end of the society’s annual meeting, held in Chicago December 3-7, 2021. She will serve in the society’s presidential line and begin her term as president in 2023.
Many people know the story of Henrietta Lacks, whose cancer cells, unknowingly taken from her 70 years ago, changed medical research. But few know the tale like CU Pharmacy Professor David Kroll, who used those cells as a graduate student and continues to pay tribute to the woman’s legacy today.
The new Center for Drug Discovery was featured on Channel 9 news. On the day of its airing the story, titled “New tool to help speed up life-saving drug treatments,” received the most views on the station’s Youtube channel!
A cutting-edge robot that will cut screening time for new drugs in half to get more effective therapies to people and animals is busy doing lifesaving work. Professor Dan LaBarbera, PhD is the founding director of the Center for Drug Discovery at CU Anschutz.
The news of the first antiviral pill to treat COVID-19 is a “very exciting development,” says Peter Anderson, PharmD, a professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences at CU Anschutz. He believes that oral pills taken at home, in combination with other medications, are the future of COVID treatments.
Professor Krishna Mallela, PhD, along with Vaibhav Upadhyay, Alexandra Lucas, Sudipta Panja, and Ryuki Miyauchi had research published in the Journal of Biological Chemistry. Dr. Mallela was also featured in this Discover magazine article title, “How COVID-19 Variants Could Outsmart Vaccines,” in which he discusses the implications of this research.
Professor David Kroll, PhD, spoke with CGTN America regarding the use of ivermectin, saying that patients should be empowered to be partners in their own healthcare, but certain organizations have lead those who are skeptical of the vaccine astray. Dr. Kroll says vaccines are the best COVID fighters, and he worries that the resolution of the pandemic will be prolonged by misinformation.